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Abstract
Background:  The Lp(a) lipoprotein (Lp(a)) consists of the polymorphic glycoprotein
apolipoprotein(a) (apo(a)), which is attached by a disulfide bond to apolipoprotein B (apoB).
Apo(a), which has high homology with plasminogen, is present only in primates and hedgehogs.
However, transgenic mice and rabbits with high serum apo(a) levels exist. Liver is the main site for
apo(a) synthesis, but the site of removal is uncertain. To examine differences between transgenic
mice expressing the LPA gene and mice capable of forming Lp(a) particles, LPA-YAC transgenic mice
and hAPOB transgenic mice were crossed and their offspring examined.
Results: Comparison of LPA-YAC with LPA-YAC/hAPOB transgenic mice showed that LPA-YAC/
hAPOB transgenic mice have higher serum total apo(a) and total cholesterol level than mice lacking
the hAPOB gene. However, hepatic apo(a) mRNA level was higher in LPA-YAC transgenic mice than
in LPA-YAC/hAPOB transgenic mice. Feeding of a high-cholesterol/high-fat diet to male LPA-YAC
transgenic mice with or without the hAPOB gene resulted in reduced serum total apo(a) and hepatic
apo(a) mRNA level.
Conclusion: In conclusion, the higher serum total apo(a) level in LPA-YAC/hAPOB transgenic mice
than in LPA-YAC transgenic mice is not caused by increased apo(a) synthesis. Lower hepatic apo(a)
mRNA level in LPA-YAC/hAPOB than in LPA-YAC transgenic mice may suggest that the increase in
total apo(a) level is a result of apo(a) accumulation in serum. Furthermore, observed higher serum
total cholesterol level in LPA-YAC/hAPOB transgenic mice than either in wild type or LPA-YAC
transgenic mice may further suggest that human APOB transgenicity is a factor that contributes to
increased serum total apo(a) and cholesterol levels. Our results on reduced serum total apo(a) and
hepatic apo(a) mRNA levels in HCHF fed male LPA-YAC transgenic mice confirm earlier findings in
females, and show that there are no sex difference in mechanisms for lowering apo(a) level in
response to HCHF feeding.
Published: 11 May 2004
Lipids in Health and Disease 2004, 3:8
Received: 20 April 2004
Accepted: 11 May 2004
This article is available from: http://www.lipidworld.com/content/3/1/8
© 2004 Teivainen et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/8
Page 2 of 12
(page number not for citation purposes)
Background
Association between Lp(a) lipoprotein (Lp(a) [1], and
coronary heart disease was first demonstrated in 1974 [2].
Afterwards, numerous studies have confirmed that high
plasma level of Lp(a) is an independent risk factor for
atherosclerotic and thrombotic disease [3]. The intact
Lp(a) molecule consists of the highly polymorphic glyco-
protein apolipoprotein(a) (apo(a)), which is attached
through a disulfide bond to apolipoprotein B-100 (apoB-
100) of low density lipoprotein (LDL).
Gene encoding for apo(a) (LPA), which expression is
mainly confined to the liver, is tightly linked to plasmino-
gen (PLG) gene on chromosome 6 and is homologous to
PLG  [4,5]. This sequence similarity indicates that the
human LPA gene evolved from a duplicated PLG gene dur-
ing primate evolution [6,7]. Interestingly, in addition to
humans, Old World monkeys, great apes and hedgehogs
are the only species, which express LPA naturally [8-10].
Varying numbers of KIV structures account for the size var-
iation of apo(a) whose size is inversely related to plasma
Lp(a) level [11]. Furthermore, recent studies in transgenic
animal models have shown that 50% of human Lp(a) is
catabolized by the liver [12,13], but the mechanism for
uptake is unclear. Study of WHHL transgenic rabbits
expressing human apo(a) showed that defect LDL recep-
tor (LDLR) lead to marked accumulation of plasma Lp(a)
[14]. However, despite structural similarity of Lp(a) to
LDL, the LDLR does not seem to be involved significantly
in Lp(a) removal in humans [15-17].
Studies in female mice transgenic for LPA-yeast artificial
chromosome (LPA-YAC), which contains a 40 kilobase
(kb)  LPA-PLG  intergenic region [18], have shown that
feeding of a high-fat diet reduces serum apo(a) and
hepatic apo(a) mRNA level [19,20]. In contrast, serum
apo(a) levels in mice transgenic for human apo(a) cDNA
are stable despite high-fat feeding [21], which suggests
that the effect of fat-rich diet on apo(a) levels in LPA-YAC
transgenic mice is most likely exerted through regulatory
elements located within the LPA-PLG intergenic region.
Recent studies on PPARα suggest that PPARα is of major
importance for regulation of serum levels of apoB and
production of apoB-containing lipoproteins [22,23], but
the possible role of PPARα in determining Lp(a) serum
level is unclear. The DNase I hypersensitive site (DH) II
enhancer part of the LPA-PLG intergenic region contains
the gene for peroxisome proliferators-activated receptor
(PPAR) α binding site [24,25]. DH II increases the activity
of the LPA promoter by over 7-fold in reporter-gene assays
in HepG2 cells in vitro [26]. This together with recent co-
transfection assays, which showed that PPARα increased
the effect of the DHII enhancer on LPA transcriptional
activity may indicate that PPARα plays a role also in deter-
mining plasma Lp(a) level [26].
In order to examine differences between transgenic mice
only expressing the LPA gene and transgenic mice capable
of forming Lp(a) particles, LPA-YAC transgenic and mice
transgenic for the human APOB (hAPOB) gene were
crossed and their offspring examined. The study revealed
that serum total apo(a) levels in LPA-YAC trangenic mice
also expressing the hAPOB gene were higher than in LPA-
YAC transgenic animals lacking hAPOB. However, hepatic
apo(a) mRNA level in LPA-YAC transgenic mice was
higher than in LPA-YAC/hAPOB transgenic mice. Further-
more, we showed that feeding of a high-cholesterol/high-
fat (HCHF) diet to male LPA-YAC transgenic mice, which
on a standard mouse diet exhibit much lower serum total
apo(a) level than female mice, reduced serum total apo(a)
and hepatic apo(a) mRNA level in a similar manner as
previously shown in female mice [19,20]. The lack of sig-
nificant variation in hepatic PPARα mRNA levels between
wild type (WT) and LPA-YAC transgenic mice or between
mice fed either a semi-synthetic mouse diet (AIN-76) or
the HCHF diet, may indicate that neither LPA transgenic-
ity nor high-fat feeding have a significant impact on
expression of PPARα.
Results
Serum apo(a) level
On a regular RMI(E)SQC mouse diet serum total apo(a)
level was significantly higher in LPA-YAC/hAPOB trans-
genic mice than in LPA-YAC transgenic mice (P < 0.05, fig-
ure 1) and serum total apo(a) levels were higher in female
transgenic mice than in respective male transgenic mice (P
< 0.005, figure 1).
Male LPA-YAC transgenic mice (n= 4) had a mean serum
total apo(a) level of 7.6 ± 2.5 mg/dL at the start and of 6.4
± 3.9 mg/dL at the end of feeding the AIN-76 diet for 7
weeks. Corresponding levels in LPA-YAC/hAPOB  trans-
genic mice (n= 6) were 9.2 ± 1.0 mg/dL and 9.5 ± 2.2 mg/
dL, respectively. Serum total apo(a) level in male LPA-
YAC/hAPOB transgenic mice was significantly reduced (P
< 0.001, figure 2) after two weeks of HCHF feeding and
the level remained low during 7 weeks of feeding. Feeding
of the HCHF diet to male LPA-YAC transgenic mice
resulted in reduced mean serum total apo(a) level from
2.9 ± 1.3 mg/dL to below background level, but because
of the small number the difference did not reach statistical
significance (P= 0.08).
Serum total cholesterol and triglycerides in male mice
LPA-YAC transgenic mice had similar serum total choles-
terol (TC) and serum triglycerides (TG) levels as WT mice,
independently of the diets (table 1). LPA-YAC/hAPOB
transgenic mice fed the AIN-76 diet had higher serum TGLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/8
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level than either WT or LPA-YAC transgenic mice (P <
0.05). The HCHF fed LPA-YAC/hAPOB transgenic mice
had significantly higher serum TC level than the AIN-76
fed mice (P < 0.005). In comparison, feeding of the HCHF
diet to WT or LPA-YAC transgenic mice had no significant
effect on serum TC levels compared to the AIN-76 fed
mice. Serum TG levels were lower in the HCHF fed LPA-
YAC and LPA-YAC/hAPOB transgenic mice compared to
the AIN-76 fed transgenic mice (P < 0.05 and P < 0.005
respectively, for the two categories of mice). The compara-
ble difference on serum TG level between the AIN-76 and
the HCHF fed WT did not reach statistical significance.
Apo(a), PPARα and LDLR mRNA levels in male mice
Apo(a) mRNA was mainly detected in liver of LPA-YAC
transgenic mice and to a very low degree in kidneys in 3
out of 4 mice (table 2). Apo(a) mRNA was not detected in
spleen, heart, brain and intestine.
On the AIN-76 diet hepatic apo(a) mRNA levels were
lower in LPA-YAC/hAPOB  than in LPA-YAC transgenic
mice (P< 0.05, figure 3). Furthermore, feeding of the
HCHF diet to transgenic mice reduced hepatic apo(a)
mRNA level significantly (P<0.05) in both strains.
Hepatic PPARα mRNA levels did not vary significantly
between WT and transgenic mice, or between the AIN-76
Serum total apo(a) level in male and female LPA-YAC and LPA-YAC/hAPOB transgenic mice on a regular RMI(E)SQC mouse diet Figure 1
Serum total apo(a) level in male and female LPA-YAC and LPA-YAC/hAPOB transgenic mice on a regular 
RMI(E)SQC mouse diet. Values shown are mean ± SEM (mg/dL). Statistically significant difference between LPA-YAC and 
LPA-YAC/hAPOB transgenic mice is indicated by # (P < 0.05) or by ## (P < 0.01). Statistically significant difference between 
respective male and female mice is indicated by * (P < 0.005).
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fed and the HCHF fed mice of the same category (figure
4).
Hepatic LDLR mRNA level did not vary significantly
between the AIN-76 fed WT, LPA-YAC and LPA-YAC/
hAPOB transgenic mice, or between the HCHF fed and the
AIN-76 fed LPA-YAC transgenic mice (figure 5). HCHF
feeding reduced LDLR mRNA levels in WT and LPA-YAC/
hAPOB  transgenic mice, compared to the levels in the
AIN-76 fed mice (P < 0.05).
Discussion
Observation of higher serum levels of total apo(a) (figure
1 & 2) in LPA-YAC/hAPOB transgenic mice than in LPA-
YAC transgenic mice are in agreement with the results of
Callow et al [27]. Our finding of lower hepatic apo(a)
mRNA levels (figure 3) in LPA-YAC/hAPOB  transgenic
mice than in mice having the LPA gene only, suggest that
the elevated serum Lp(a) levels in LPA-YAC/hAPOB trans-
genic mice are not due to increased hepatic apo(a) mRNA
transcription rate. Furthermore, analysis of LPA expres-
sion in different tissues (table 2) indicates that no other
organs than the liver, can produce significant amounts of
apo(a).
LDL can be removed from the circulation by the LDL
receptor (LDLR), which binds to the apoB-100 part of LDL
[28]. The efficient assembly of Lp(a) in mice transgenic for
Effect of 7 weeks HCHF feeding on serum total apo(a) level in male LPA-YAC and LPA-YAC/hAPOB transgenic mice Figure 2
Effect of 7 weeks HCHF feeding on serum total apo(a) level in male LPA-YAC and LPA-YAC/hAPOB transgenic 
mice. Mice were fed the HCHF diet for 7 weeks. Mice were bled at the start, after 2 weeks of feeding and when the animals 
were sacrificed. Values shown are mean ± SEM (mg/dL) of serum total apo(a) level. According to manufacturer, values <1.2 mg/
dL reflect background noise. The * indicates statistically significant difference (P < 0.001) in comparison to the start level. Sta-
tistically significant difference (P < 0.05) between LPA-YAC and LPA-YAC/hAPOB transgenic mice is indicated by #.
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both  LPA  and  hAPOB  and higher efficiency of Lp(a)
assembly with the human apoB-100 than with mouse
apoB-100 [29,30] may suggest that measured total apo(a)
level in LPA-YAC/hAPOB transgenic mice consist mainly
of human Lp(a) particles.
Because mouse LDLR has low capacity to bind human
apoB-100 containing particles [31], elevated serum total
apo(a) level may theoretically be secondary effect of
reduced clearance rate of human apoB containing parti-
cles via the LDLR dependent pathway in LPA-YAC/hAPOB
transgenic mice. Support for this comes from study, which
showed that overexpression of LDLR in mice leads to
accelerated metabolism of injected human Lp(a) particles
[32]. Furthermore, it is notable that serum Lp(a) levels in
LDLR-/-/LPA transgenic mice are similar whether or not
the human APOB gene is also present [33]. Since triglycer-
ide-rich apoB particles have increased affinity to apo(a) in
man [34,35], it seems likely that the human apoB part of
the Lp(a) molecule in mouse serum may associate with
TG containing particles, which may explain why hAPOB
transgenicity also contributes to increased serum TG
levels.
Suggestion for a role of LDLR in Lp(a) clearance comes
also from studies in rabbits, where apoB, in contrast to
mice, associates with human apo(a) forming Lp(a) parti-
cles [36]. A defect in LDLR in LPA transgenic WHHL rab-
bits is accompanied by accumulation of Lp(a) in plasma
[14]. Since mice or rabbits do not normally have apo(a),
the mechanism of Lp(a) removal in these animals may
well differ from that in man, where the LDLR does not
seem to affect Lp(a) metabolism [15-17].
The fall in serum apo(a) and hepatic apo(a) mRNA levels
(figure 2 and 3) in male transgenic mice on the HCHF diet
agrees with observations by Acquati et al and Huby et al,
who showed that hepatic apo(a) mRNA and serum apo(a)
levels fell in female LPA transgenic mice after two weeks
fat feeding [19,20]. Man, who naturally express LPA, do
not have significant variation in plasma Lp(a) levels
despite of changes in diet [37]. This indicates that man
possesses LPA control mechanisms that are different from
Table 1: Serum triglycerides (TG) and serum total cholesterol (TC) levels in male WT, LPA-YAC transgenic and LPA-YAC/hAPOB 
transgenic mice
AIN-76 diet HCHF diet
Mice n TG (mmol/L) n TG (mmol/L)
WT 5 1.8 ± 0.3 5 1.2 ± 0.3
LPA-YAC 4 1.9 ± 0.2 3 2)1.1 ± 0.2
LPA-YAC/hAPOB 6 1)3.1 ± 0.2 8 2)1.4 ± 0.1
Mice n TC (mmol/L) n TC (mmol/L)
WT 5 5.2 ± 0.4 5 6.3 ± 0.2
LPA-YAC 4 5.3 ± 0.2 3 5.7 ± 0.2
LPA-YAC/hAPOB 66 . 0  ±  0 . 3 83)15.0 ± 0.9
Concentrations are presented as mean ± SEM (mmol/L). 1): Statistically significant difference (P < 0.05) in serum TG levels as compared to the AIN-
76 fed WT or LPA-YAC transgenic mice. 2): Statistically significant difference in serum TG levels as compared to the respective AIN-76 fed mice (P 
< 0.05 for LPA-YAC, P < 0.005 for LPA-YAC/hAPOB). 3): Statistically significant difference (P < 0.005) in serum TC levels as compared to the AIN-76 
fed LPA-YAC/hAPOB transgenic mice.
Table 2: LPA expression level in different tissues of 1-year old male LPA-YAC transgenic mice on a regular RMI(E)SQC mouse diet
LPA expression
Mice n Liver Spleen Heart Brain Intestine Kidney
LPA- Y A C 4H i g h ----L o w
W T 2------Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/8
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those in mice. This agrees with the fact that CYP7A1,
which regulates the initial step in the pathway of
cholesterol metabolism and bile acid synthesis, is
increased during cholesterol feeding in rats and mice, but
not in humans [38]. Rodents' capacity to convert
cholesterol into bile acids by liver X receptor-α mediated
stimulation of CYP7A1 transcription has been suggested
to account for some of the differences in response to fat
intake between humans and rodents [39]. Furthermore,
PPARα, which binds to the DHII enhancer part of LPA-
PLG intergenic region [24], and is of importance for pro-
duction of apoB and apoB-containing lipoproteins [22],
was recently shown to be regulated by bile acids in
humans but not in rodents [40]. Since cholesterol feeding
promotes bile acid synthesis in rodents [41], our results
showing similar hepatic PPARα mRNA levels between the
AIN-76 and HCHF fed mice may give further support to
the notion that bile acids do not increase PPARα mRNA
levels in mice. Further studies will be needed to elucidate
whether or not the species-specific differences in choles-
terol and bile acid metabolism is a key to understanding
the mechanism(s), which cause the reduction on apo(a)
transcription in HCHF fed transgenic mice.
The reduced hepatic LDLR mRNA level seen in HCHF fed
WT mice and LPA-YAC/hAPOB transgenic mice (figure 5)
is in agreement with previous results, which showed that
hepatic LDLR level in mice is reduced in response to
HCHF feeding [42]. This may suggest that the human
apoB can interact sufficiently, although less than mouse
Median of normalized hepatic apo(a) mRNA level in male LPA-YAC and LPA-YAC/hAPOB transgenic mice fed the AIN-76 diet or  the HCHF diet for 7 weeks Figure 3
Median of normalized hepatic apo(a) mRNA level in male LPA-YAC and LPA-YAC/hAPOB transgenic mice fed 
the AIN-76 diet or the HCHF diet for 7 weeks. The * indicates statistically significant difference (P < 0.05) in comparison 
to the level in the AIN-76 fed mice. Statistically significant difference (P < 0.05) between LPA-YAC and LPA-YAChAPOB trans-
genic mice is indicated by #.
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apoB, with mouse LDLR to increase intracellular level of
cholesterol and down regulate expression of the LDLR.
Because of the small number of HCHF fed LPA-YAC trans-
genic mice in our study, the absence of an effect of feeding
on LDLR mRNA level must be confirmed in further
studies.
On the HCHF diet both WT mice and transgenic mice
developed fatty livers (not shown). Since hepatic level
either of housekeeping genes or PPARα mRNA was not
reduced in response to the HCHF feeding, it seems clear
that the decreased apo(a) mRNA level detected in the
livers of HCHF fed transgenic mice was not due to a gen-
eral decrease in liver function.
Conclusions
In conclusion, we have shown that serum total apo(a)
level is higher in LPA-YAC/hAPOB transgenic mice than in
mice that are transgenic for the LPA  gene alone. The
higher level is not caused by increased apo(a) synthesis.
Lower hepatic apo(a) mRNA level in LPA-YAC/hAPOB
than in LPA-YAC transgenic mice may suggest that the
increase in total apo(a) level is a result of apo(a)
accumulation in serum. Our results on reduced serum
total apo(a) and hepatic apo(a) mRNA level in HCHF fed
male LPA-YAC transgenic mice confirm earlier findings in
females, and show that there are no sex difference in
mechanisms for lowering apo(a) level in response to
HCHF feeding.
Median of normalized hepatic PPARα mRNA level in male WT, LPA-YAC and LPA-YAC/hAPOB transgenic mice fed the AIN-76  or the HCHF diet for 7 weeks Figure 4
Median of normalized hepatic PPARα mRNA level in male WT, LPA-YAC and LPA-YAC/hAPOB transgenic 
mice fed the AIN-76 or the HCHF diet for 7 weeks.
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Materials and methods
Mice
Mice possessing a 270 kb YAC with a human genomic
DNA clone containing the intact LPA gene and a 70 kb
LPA-like gene with extensive 60 kb flanking regions on
both sides and mice possessing the intact hAPOB gene in
FVB genetic background have been described previously
[18,27]. Non-transgenic FVB mice were purchased from
Harland (Bicester, England). For experiments in Oslo,
mice were bred at The Laboratory Animal Unit, which is
fully accredited by AAALAC (Association for Assessment
and Accreditation of Laboratory Animal Care and Use), at
The Norwegian School for Veterinary Science. The Norwe-
gian Animal Research Authority approved the experi-
ments and all animal experiments were performed in
accordance with the Norwegian Gene Technology Act of
1994 and the European Community Directive of 24
November 1986.
To develop mice capable of forming Lp(a) particles, LPA-
YAC transgenic mice and hAPOB  transgenic mice were
crossed. Sentinel animals were used to run a full felasa-
style health-monitoring scheme and mice were found to
be healthy.
The presence of the LPA gene and the hAPOB gene was
demonstrated by PCR analysis [43]. For the analysis of
hAPOB  transgenicity sense primer TGGAAACGGA-
GAAATTATGGA and antisense primer CACTTGGCAAAT-
ACAATTCCTG were used.
Median of normalized hepatic LDLR mRNA level in male WT, LPA-YAC or LPA-YAC /hAPOB transgenic mice fed the AIN-76 or  the HCHF diet for 7 weeks Figure 5
Median of normalized hepatic LDLR mRNA level in male WT, LPA-YAC or LPA-YAC/hAPOB transgenic mice 
fed the AIN-76 or the HCHF diet for 7 weeks. Statistically significant difference (P < 0.05) between the AIN-76 fed and 
the HCHF fed mice is indicated by *.
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Mice were housed in a room with 12 h light/dark cycle
and 55% relative humidity at 21°C. Mice were kept on the
regular RMI(E)SQC mouse diet (Special Diet Services,
Witham, Essex, England) until the start of the feeding
experiment.
Four 1-year old male LPA-YAC transgenic mice and two 1-
year old male wild type mice were sacrificed for the study
of LPA expression pattern. For the study of serum total
apo(a) level prior to the feeding experiment, six female
and seven male LPA-YAC transgenic as well as five female
and fifteen male LPA-YAC/hAPOB transgenic mice were
bled.
Feeding experiment
Ten male WT, seven LPA-YAC transgenic and fourteen
LPA-YAC/hAPOB  transgenic mice were divided into
groups and fed with a semi-synthetic mouse diet (AIN-76,
ICN, Asse-Relegem, Belgium) or a high-cholesterol/high-
fat diet (Custom high-fat diet, ICN, Asse-Relegem, Bel-
gium) for seven weeks (table 3). The HCHF diet contained
1.25% cholesterol, 18.4% regular butter, corresponding
to approximately 9% saturated fat, and 1% corn oil, while
the AIN-76 diet contained 5% corn oil. Corn oil contains
approximately 1.7% saturated fat. Water and food were
given ad libitum. In addition to the blood sampling
before feeding, blood samples from the saphenous vein
were drawn after two weeks feeding and when the animals
were sacrificed after seven weeks feeding.
Analysis of serum total apo(a), total cholesterol and 
triglycerides level
Serum total apo(a) level was measured using a radioim-
muno assay (RIA) kit (Mercodia AB, Uppsala, Sweden).
This method is based on direct sandwich technique in
which two monoclonal antibodies are directed against
separate antigenic determinants of apo(a). Results are
given in units per liter (U/L). According to the manufac-
turer, results must be multiplied by 0.07 to obtain values
in mg/dL, and levels below 1.2 mg/dL (17 U/L) are con-
sidered as background noise. For details of test's reliability
to measure serum apo(a) level see Berg et al [43].
Serum TC and TG level was measured using enzymatic,
colorimetric methods (Modular Analytics, Roche
Diagnostics, F-Hoffmann-La Roche Ltd, Basel, Switzer-
land) at Fürst AS, Oslo, Norway.
Tissue preparation for mRNA analysis
For RNA preparations, tissue samples were washed in ice-
cold saline, submerged in RNAlater™ buffer (Ambion
Diagnostics, Cambridgeshire, England) and stored at -
70°C until analysis.
Quantitative PCR
Level of mRNA was determined by quantitative PCR
(qPCR), which was performed using the ABI PRISM 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Primers and probes (table 4) were
designed using Primer Express software (Applied Biosys-
tems, Foster City, CA, USA).
Total RNA from 100–300 mg of tissues was isolated after
homogenisation in 1 ml Trizol reagent according to the
manufacturer's recommendations (Invitrogen Co,
Carlsbad, CA, USA). RNA was treated with Dnase I
(Ambion Ltd, Cambridgeshire, England) and 5 µg of total
RNA was reverse-transcribed using pd(N)6 random prim-
ers (First strand cDNA synthesis kit, Amersham Bio-
sciences, Little Chalfont Buckinghamshire, England).
Table 3: Age at the start and number of mice fed different diets 
for 7 weeks
Mice Age (weeks) AIN-76 diet HCHF diet
WT 44–47 5 5
LPA-YAC 49–52 4 3
LPA-YAC/hAPOB 49–52 6 8
Table 4: Primer and probe sequences for cyclophilin, β-actin, LPA, PPARα and LDLR genes used in qPCR
Gene Forward primer Reverse primer Probe
Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGA CGGGACAAGCCACTGAAGGATGT
β-actin ACGAGGCCCAGAGCAAGAG CGTCCCAGTTGGTAACAATGC ATGTTCAATGGGGTACTTCAGGGTCAGGA
LPA TTGTCTGCCATCCCCAGACTAC AGGCCAGTC CCAAAGGTACCT TGGTCACCGCCAGGACTGAATGTTACA
PPARα TGAGATGGCAGGCCGTTAC AAATCCCTGCTCTCCTGTATGG ACTGTTCAGGGACCTCCGAGGCCT
LDLR GCTCCATAGGCTATCTGCTCTTCA CTGCGGTCCAGGGTCATC CAACCGCCACGAGGTCCGGALipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/8
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qPCR was performed using the TaqMan® Universal Master
mix (Applied Biosystems, Foster City, CA, USA) contain-
ing 2 µl cDNA, 300 nM of each primer and probe in a 25
µl final volume. To evaluate the qPCR performances,
cDNA samples, made as described above, from liver of
five ten week's old WT male mice were analyzed for β-
actin and cyclophilin mRNA levels. We run triplicates of
1:100 diluted cDNA samples for each mouse. Variance of
Ct values at the same threshold for within-run and
between-runs is presented in table 5. Analysis of genes of
interest was carried out in a duplicate and relative mRNA
level was determined by the Standard Curve Method
(User Bulletin No. 2, Applied Biosystems). PCR cycle
parameters were as follows: 1 cycle of 50°C for 2 min and
95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C
for 1 min. The level of mRNA was normalized to average
of cyclophilin and β-actin RNA levels to compensate for
variations in input RNA amounts and are presented as
median level of normalized mRNA level. In a case of
analysis of LPA  expression pattern in different tissues,
samples were screened qualitatively by qPCR and expres-
sion level is presented as high, low or not expressed (-).
LPA primers and probe (Eurogentech, Seraing, Belgium)
were designed to bind specifically to the KV part of the
LPA gene. Because of the high degree of sequence homol-
ogy between the LPA and PLG genes, specificity of LPA
primers and probes was tested by running PCR reactions
with different concentrations of plasmid containing PLG
gene or LPA plasmid construct without KV (a kind gift
from Dr. S. Frank, University of Graz, Austria). There was
no detectable PCR product when these plasmids were
used as templates in the PCR reaction. cDNA made from
RNA isolated from the liver of WT mouse was used as a
negative control when analyzing the transgenes.
Because of poor RNA quality, two samples were excluded
from analysis.
Statistical analyses
The non-parametric Mann-Whitney test was used to ana-
lyse differences between groups. All data from serum anal-
ysis are presented as mean ± SEM. In the case of mRNA
data, results are presented as median value of normalized
mRNA level.
List of abbreviations
Apo(a) = apolipoprotein(a)
HCHF = high-cholesterol/high-fat (diet)
LDL = low density lipoprotein
LDLR = LDL receptor
Lp(a) = lipoprotein(a)
LPA = gene encoding for apolipoprotein(a)
TG = triglycerides
TC = total cholesterol
WT = wild type (mouse)
Table 5: Variation in A) β-actin and B) cyclophilin mRNA levels in five mouse livers submitted to qPCR. Calculations of variations were 
based on measured Ct value at the same threshold level.
A) β-actin Within-run (SD) Between-run (SD) CV% No. of observations
Mouse 1 0.02 0.17 0.78 9
Mouse 2 0.11 0.27 1.25 9
Mouse 3 0.09 0.36 1.63 9
Mouse 4 0.09 0.29 1.31 9
Mouse 5 0.23 0.27 1.24 9
All samples 0.22 0.36 1.66 45
B) Cyclophilin Within-run (SD) Between-run (SD) CV% No. of observations
Mouse 1 0.25 0.18 0.76 6
Mouse 2 0.02 0.06 1.24 6
Mouse 3 0.43 0.32 1.27 6
Mouse 4 0.06 0.26 1.06 6
Mouse 5 0.23 0.17 0.69 6
All samples 0.25 0.27 1.11 30Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/8
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